- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Injections of tirzepatide.
Type 2 diabetes (NIDDM) not controlled by diet,weight loss & exercise alone
Treatment of adults with insufficient controlled type 2 diabetes mellitus:
As monotherapy when metformin is considered inappropriate due to intolerance or contraindications.
In combination with other glucose lowering medication including insulin where the existing regimen with diet and exercise does not provide adequate glycaemic control.
2.5mg once a week for 4 weeks.
A dose increased of 2.5mg can occur after 4 weeks of the current dose.
5mg to 15mg once a week.
Maximum dose is 15mg once a week.
Additional Dosage Information
When tirzepatide is used in combination with insulin or a sulfonylurea, a lower dose of insulin or a sulfonylurea may be considered to reduce the risk of hypoglycaemia.
Within 4 days
Administer the missed dose as soon as possible.
More than 4 days
Skip the missed dose and administer the next scheduled dose.
For subcutaneous injection into the abdomen, thigh or upper arm. Rotate injection sites between each dose.
To be administered once a week at any time of the day, can be given with or without meals.
Children under 18 years
Precautions and Warnings
Patients over 85 years
Diabetic macular oedema
End stage renal disease
History of pancreatitis
Proliferative diabetic retinopathy
Severe gastrointestinal disorder
Severe hepatic impairment
Severe renal impairment
For subcutaneous use only
Monitor patient for hypoglycaemia if adjunct to insulin or sulfonylurea
Advise patient to seek medical advice if symptoms of dehydration occur
Advise patients to report symptoms of acute pancreatitis immediately
Discontinue if pancreatitis is suspected
Do not restart treatment following confirmation of pancreatitis
Advise patient on fluid replacement if GI side effects occur
Patient to inform DVLA if fitness to drive impaired or hypoglycaemic risk
Pregnancy and Lactation
Tirzepatide is contraindicated during pregnancy.
The manufacturer does not recommend the use of tirzepatide during pregnancy. Animal studies have indicated reproductive toxicity.
Tirzepatide is contraindicated during breastfeeding.
The manufacturer states a decision must be made as to discontinue breastfeeding or tirzepatide taking into account the benefits of breastfeeding for the child and the benefits of the therapy for the mother. Presence of tirzepatide excretion in human milk is unknown, a risk to the newborn cannot be excluded.
Elevated amylase levels
Elevated serum lipase
Gastroesophageal reflux disease
Increased heart rate
Increased serum calcitonin
Injection site reactions
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: December 2022
Summary of Product Characteristics: Mounjaro 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg solution for injection in pre-filled pen. Eli Lilly and Company Limited. Revised September 2022.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.